We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Immunovant Stock Surges 17% in 3 Months: What's Driving It?
Read MoreHide Full Article
Key Takeaways
IMVT shares have risen 17% in three months as progress in its autoimmune pipeline boosts investor confidence.
Immunovant is advancing IMVT-1402, with several top-line data readouts expected in 2026 and 2027.
IMVT ended 2025 with $994.5M in cash after a $550M financing.
Shares of Immunovant (IMVT - Free Report) have surged 17% over the past three months, reflecting improving investor confidence, driven by encouraging pipeline progress and a strong financial position.
Immunovant’s Progress With IMVT-1402
The company continues advancing its lead next-generation neonatal fragment crystallizable receptor (FcRn) inhibitor,IMVT-1402, across multiple autoimmune indications, including potentially registrational studies in Graves’ disease (GD), difficult-to-treat rheumatoid arthritis (D2T RA), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy and Sjögren’s disease, as well as a proof-of-concept trial in cutaneous lupus erythematosus (CLE).
Immunovant recently completed enrollment in the open-label portion of the potentially registrational trial of IMVT-1402 in D2T RA, with top-line data expected in the second half of 2026. Top-line data from potentially registrational clinical studies evaluating IMVT-1402 for the treatment of patients with GD and MG are anticipated in 2027. Immunovant expects top-line data from the CLE proof-of-concept study of IMVT-1402 in the second half of 2026.
Besides its lead candidate, Immunovant is also evaluating its second candidate, batoclimab, a fully human monoclonal antibody targeting FcRn, in ongoing mid-to-late-stage studies for two autoimmune indications, GD and thyroid eye disease (TED). The company expects to report top-line data from its two late-stage clinical studies for the treatment of patients with active, moderate-to-severe TED in the first half of 2026.
These clearly defined development milestones and upcoming catalysts have strengthened investor sentiment.
Over the past year, Immunovant shares have surged 40% compared with the industry’s 14.7% growth.
Image Source: Zacks Investment Research
Strong Cash Position
The company’s financial position has improved significantly following a December 2025 underwritten financing that raised approximately $550 million from institutional investors, including Roivant Sciences.
As of Dec. 31, 2025, Immunovant’s cash and cash equivalents totaled $994.5 million, providing substantial liquidity to fund ongoing clinical programs and extending its cash runway through the potential commercial launch of IMVT-1402 for GD.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.54 to $2.82. CPRX shares have gained 14% over the past year.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $8.08 to $8.22 for 2026. Over the past year, shares of ANIP have surged 25.3%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.
Over the past 60 days, estimates for Assertio’s 2026 loss per share have narrowed from 30 cents to 28 cents. ASRT shares have lost 0.6% over the past year.
Assertio’s earnings beat estimates in one of the trailing four quarters and missed in the remaining three, with the average negative surprise being 35.21%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Immunovant Stock Surges 17% in 3 Months: What's Driving It?
Key Takeaways
Shares of Immunovant (IMVT - Free Report) have surged 17% over the past three months, reflecting improving investor confidence, driven by encouraging pipeline progress and a strong financial position.
Immunovant’s Progress With IMVT-1402
The company continues advancing its lead next-generation neonatal fragment crystallizable receptor (FcRn) inhibitor,IMVT-1402, across multiple autoimmune indications, including potentially registrational studies in Graves’ disease (GD), difficult-to-treat rheumatoid arthritis (D2T RA), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy and Sjögren’s disease, as well as a proof-of-concept trial in cutaneous lupus erythematosus (CLE).
Immunovant recently completed enrollment in the open-label portion of the potentially registrational trial of IMVT-1402 in D2T RA, with top-line data expected in the second half of 2026. Top-line data from potentially registrational clinical studies evaluating IMVT-1402 for the treatment of patients with GD and MG are anticipated in 2027. Immunovant expects top-line data from the CLE proof-of-concept study of IMVT-1402 in the second half of 2026.
Besides its lead candidate, Immunovant is also evaluating its second candidate, batoclimab, a fully human monoclonal antibody targeting FcRn, in ongoing mid-to-late-stage studies for two autoimmune indications, GD and thyroid eye disease (TED). The company expects to report top-line data from its two late-stage clinical studies for the treatment of patients with active, moderate-to-severe TED in the first half of 2026.
These clearly defined development milestones and upcoming catalysts have strengthened investor sentiment.
Over the past year, Immunovant shares have surged 40% compared with the industry’s 14.7% growth.
Image Source: Zacks Investment Research
Strong Cash Position
The company’s financial position has improved significantly following a December 2025 underwritten financing that raised approximately $550 million from institutional investors, including Roivant Sciences.
As of Dec. 31, 2025, Immunovant’s cash and cash equivalents totaled $994.5 million, providing substantial liquidity to fund ongoing clinical programs and extending its cash runway through the potential commercial launch of IMVT-1402 for GD.
Immunovant, Inc. Price and Consensus
Immunovant, Inc. price-consensus-chart | Immunovant, Inc. Quote
IMVT’s Zacks Rank & Stocks to Consider
Immunovant currently carries a Zacks Rank #3 (Hold).
Some top-ranked stocks in the biotech sector are Catalyst Pharmaceuticals (CPRX - Free Report) , which currently sports a Zacks Rank #1 (Strong Buy), Assertio Holdings (ASRT - Free Report) and ANI Pharmaceuticals (ANIP - Free Report) , both carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.54 to $2.82. CPRX shares have gained 14% over the past year.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $8.08 to $8.22 for 2026. Over the past year, shares of ANIP have surged 25.3%.
ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%.
Over the past 60 days, estimates for Assertio’s 2026 loss per share have narrowed from 30 cents to 28 cents. ASRT shares have lost 0.6% over the past year.
Assertio’s earnings beat estimates in one of the trailing four quarters and missed in the remaining three, with the average negative surprise being 35.21%.